Go Pro
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel Free CALA Stock Alerts

Calithera Biosciences (CALA) Competitors

Calithera Biosciences logo
$0.0003 0.00 (0.00%)
As of 09/2/2026
Compare

CALA vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Calithera Biosciences stock or one of its competitors? Calithera Biosciences's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Calithera Biosciences compare to 60 Degrees Pharmaceuticals?

Calithera Biosciences (NASDAQ:CALA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Calithera Biosciences. 60 Degrees Pharmaceuticals' average media sentiment score of 1.99 beat Calithera Biosciences' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Calithera Biosciences Neutral
60 Degrees Pharmaceuticals Very Positive

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

60 Degrees Pharmaceuticals has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats Calithera Biosciences on 3 of the 3 factors compared between the two stocks.

How does Calithera Biosciences compare to Biofrontera?

Calithera Biosciences (NASDAQ:CALA) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Biofrontera has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Biofrontera$46.18MN/AN/AN/AN/A

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Biofrontera Neutral

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Biofrontera N/A N/A N/A

Summary

Biofrontera beats Calithera Biosciences on 1 of the 1 factors compared between the two stocks.

How does Calithera Biosciences compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Calithera Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

In the previous week, Cingulate's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Cingulate Neutral
Calithera Biosciences Neutral

Summary

Cingulate and Calithera Biosciences tied by winning 0 of the 0 factors compared between the two stocks.

How does Calithera Biosciences compare to Clever Leaves?

Calithera Biosciences (NASDAQ:CALA) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

Clever Leaves has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

Calithera Biosciences has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3845.97, meaning that its share price is 384,497% more volatile than the broader market.

6.9% of Clever Leaves shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Clever Leaves Neutral

Summary

Clever Leaves beats Calithera Biosciences on 6 of the 6 factors compared between the two stocks.

How does Calithera Biosciences compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Calithera Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Summary

Comera Life Sciences beats Calithera Biosciences on 1 of the 1 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALA vs. The Competition

Export
MetricCalithera BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.25B$7.26B$12.73B
Dividend YieldN/A2.59%2.53%8.86%
P/E Ratio0.00787.27273.2925.25
Price / SalesN/A754.88623.6797.64
Price / CashN/A94.8077.8252.26
Price / BookN/A12.3312.926.14
Net Income-$39.65M$2.82B$3.47B$349.01M
7 Day PerformanceN/A2.60%0.60%-0.27%
1 Month PerformanceN/A6.96%5.72%0.68%
1 Year PerformanceN/A9.45%25.33%14.84%

Calithera Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALA
Calithera Biosciences
N/A$0.00
flat		N/A+200.0%$1KN/AN/A60
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/A-62.0%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.03
+13.1%		N/A-83.7%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
+44.3%		N/A-84.3%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/AN/A$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel